LDL cholesterol blood test
LDL cholesterol. Also called: LDL-C, Low-density lipoprotein cholesterol, "Bad" cholesterol
LDL cholesterol is the cholesterol carried in low-density lipoprotein, the main particle that builds plaque in artery walls. Below 100 mg/dL is optimal; 160 or higher is high. Lowering it reduces heart attacks and strokes, which makes it the main treatment target.
One of the four values on a standard Lipid Panel. The panel page also covers the advanced tests, ApoB and Lp(a).
At a glance
| What it measures | The cholesterol carried in low-density lipoprotein (LDL), the particle that deposits cholesterol in artery walls. |
|---|---|
| Sample | Serum or plasma. Usually calculated from a lipid panel; a direct test is available. Fasting is not required. |
| Adult categories | Optimal below 100 mg/dL; near optimal 100-129; borderline high 130-159; high 160-189; very high 190 or higher. |
| Peptides that move it | Lowered slightly by Tirzepatide, Semaglutide and Liraglutide; raised by Goserelin and Leuprolide. |
| Lab code | LOINC 2089-1; calculated 13457-7, direct 18262-6 (Labcorp 303756/120295, Quest 7600/8293) |
What is LDL cholesterol?
LDL cholesterol is the cholesterol inside low-density lipoprotein particles. It is the main target of cholesterol treatment: in statin trials, lowering it reduced heart attacks, strokes and revascularizations. Most lipid panels calculate LDL from total cholesterol, HDL and triglycerides; Labcorp now uses the NIH equation for this. A direct LDL test measures it instead.
How it is made and regulated
Where it is made
LDL is removed from the blood through the LDL-receptor pathway that Brown and Goldstein described. Mutations in the LDL receptor or APOB genes, and in PCSK9, cause autosomal dominant hypercholesterolemia, with high LDL from birth.
What controls it
Diet, body weight, physical activity and genes set LDL. ATP III notes that regular physical activity lowers LDL in some people, and lists diabetes, hypothyroidism, obstructive liver disease, chronic kidney failure and drugs such as progestins, anabolic steroids and corticosteroids as secondary causes of high LDL.
How it travels in the blood
Most labs calculate LDL. The Friedewald formula (1972) estimated it without an ultracentrifuge; the NIH equation (2020) was built to stay accurate when LDL is low or triglycerides are high, where Friedewald is less accurate at triglycerides of 400 mg/dL or more. Labcorp's panel reports "LDL Chol Calc (NIH)", and Labcorp and Quest also offer a direct LDL assay.
Sources: [10] [4] [3] [5] [11]
How long it lasts
LDL responds to treatment within weeks: the 2026 ACC/AHA guideline reassesses lipids after starting or changing treatment, looking at both the percentage fall and the level reached. The 2018 guideline it replaced rechecked at 4 to 12 weeks. A normal meal lowers LDL by about 8 mg/dL at most, so a non-fasting sample works.
What it does
Lowering LDL lowers risk. In the Cholesterol Treatment Trialists' meta-analysis, more intensive statin therapy gave a further 15% reduction in major vascular events. Genetic evidence points the same way: a genetic score that raises LDL also raised heart-attack risk, while one that raises HDL did not lower it.
Reference ranges
LDL is read against treatment categories. Labcorp prints 0-99 mg/dL for calculated and direct LDL; Quest prints below 100 for adults and below 110 under age 20; ATP III sets five categories from optimal to very high.
Labcorp (test 303756)
| Group | Range (mg/dL) |
|---|---|
| Calculated LDL (NIH equation), adults | 0-99 |
| Direct LDL (test 120295; sample report for a 32-year-old man) | 0-99 |
Results above 99 are flagged high. Labcorp adds a comment to consider familial hypercholesterolemia at very high LDL.
Quest Diagnostics (test 7600 / 8293)
| Group | Range (mg/dL) |
|---|---|
| 20 years and older | <100 |
Children and teens
| Group | Range (mg/dL) |
|---|---|
| Under 20 years | <110 |
Quest prints the same limits for calculated LDL (panel 7600) and direct LDL (8293).
NCEP Adult Treatment Panel III (NHLBI)
| Group | Range (mg/dL) |
|---|---|
| Optimal | <100 |
| Near optimal/above optimal | 100-129 |
| Borderline high | 130-159 |
| High | 160-189 |
| Very high | 190 or higher |
Adult categories from ATP III Table 2. The 2018 AHA/ACC guideline called 190 mg/dL or higher severe hypercholesterolemia; every adult at that level is eligible for a statin under the 2026 ACC/AHA guideline too.
Your treatment target depends on your overall risk, not only on the category. Calculated LDL is less reliable when triglycerides are very high; ask for a direct LDL then.
Units: Labs outside the US report LDL in mmol/L. Divide mg/dL by 38.6 to convert: 100 mg/dL is about 2.6 mmol/L and 190 mg/dL about 4.9 mmol/L. [12]
Is there an "optimal" range?
There is no single LDL target: the right number depends on your risk.
Below 100 mg/dL is optimal
<100 mg/dL
NCEP ATP III
The lowest of its five LDL categories.
Goals set by your risk
Below 100 mg/dL at borderline or intermediate risk; below 70 at high risk or with heart disease; below 55 at very high risk
2026 ACC/AHA guideline
The 2026 guideline brings back explicit LDL goals matched to cardiovascular risk; the 2018 guideline it replaced used 70 mg/dL only as the point to consider adding a non-statin drug.
Judge by the percentage fall and the level reached
A 30-49% fall at borderline or intermediate risk; 50% or more at high risk
2026 ACC/AHA guideline
Response is judged by both the percentage fall from baseline and the LDL reached; the 2018 guideline used the percentage fall alone.
What raises it
| Factor | How | How much |
|---|---|---|
| Inherited hypercholesterolemia (LDLR, APOB, PCSK9)Condition | Weaker LDL clearance raises LDL from birth. | 190 mg/dL or higher counts as severe hypercholesterolemia [7] [2] |
| Hypothyroidism, obstructive liver disease, chronic kidney failure, diabetesCondition | Secondary causes of high LDL listed by ATP III. | No published magnitude [8] |
| Progestins, anabolic steroids, corticosteroidsMedication | ATP III lists these as drugs that raise LDL and lower HDL. | No published magnitude [8] |
| GnRH drugs (Goserelin, Leuprolide)Peptide | Sex-hormone suppression raises LDL. | +21.3 mg/dL on goserelin over 6 months in women with endometriosis [19] [20] |
What lowers it
| Factor | How | How much |
|---|---|---|
| StatinsMedication | Statins remain the foundation of LDL lowering in the 2026 ACC/AHA guideline, as they were in 2018. | High-intensity -50% or more; moderate-intensity -30% to -49% [2] [13] [14] |
| Physical activity, weight control, less saturated fatLifestyle | ATP III's lifestyle measures; activity lowers LDL in some people. | No published magnitude [8] |
| GLP-1 and GIP/GLP-1 drugsPeptide | Tirzepatide lowered LDL modestly in its obesity trial. | -7.1% vs -1.7% on placebo (tirzepatide 15 mg) [21] |
Peptides that affect LDL cholesterol
How each peptide in our library changes LDL cholesterol, from FDA label tables and trials. None of these is an LDL-lowering drug: the falls are small next to statins. No study has measured LDL cholesterol after dosing CJC-1295, Ipamorelin, HGH Fragment 176-191 or AOD-9604; a PubMed search for each peptide with cholesterol, triglycerides or lipids finds no human data (the only AOD-9604 lipid paper is a mouse study of fat loss, not blood lipids).
| Peptide | Effect on LDL cholesterol | Size of effect | Evidence |
|---|---|---|---|
| Dulaglutide | Lowers | No figure in the abstract: a retrospective review of 55 adults with type 2 diabetes on dulaglutide 1.5 mg found LDL fell significantly after 24 months (p < 0.001); there was no comparison groupObservational evidence only; there is no placebo comparison. [22] | Human trials |
| MK-677 (Ibutamoren) | Unclear | Older adults (2 years): LDL fell -5.4 mg/dL from baseline on MK-677 (P = 0.026). Obese men: LDL was not significantly changedOne small within-group fall, one null result. [23] [24] | Human trials |
| Goserelin | Raises | Women treated for endometriosis, 6 months: LDL rose 21.3 mg/dL on goserelin (33.3 mg/dL on danazol)An LDL rise during estrogen suppression; danazol raised it more. [19] | FDA label |
| Leuprolide | Raises | No size given: hyperlipidemia including LDL-cholesterol was recorded in 5% or more of men with prostate cancerThe label asks for lipid monitoring on GnRH agonists. [20] | FDA label |
| Liraglutide | Lowers | Saxenda 3 mg (Study 1, adults without diabetes): LDL -3.1% vs -0.7% on placebo; relative difference -2.4%A small fall in the weight-management trial. [25] | FDA label |
| Semaglutide | Lowers | Wegovy 2.4 mg, 68 weeks (adults with obesity or overweight): LDL -2.5% vs +1.3% on placebo; relative difference -3.8%A small LDL fall; semaglutide is not an LDL-lowering drug. [26] | FDA label |
| Tirzepatide | Lowers | Zepbound 15 mg, 72 weeks (Study 1): LDL -7.1% vs -1.7% on placebo; relative difference -5.5%A modest fall, far smaller than with statins. [21] | FDA label |
What high or low results can mean
A high result
160-189 mg/dL is high and 190 or higher very high. At 190 or higher, the 2018 AHA/ACC guideline treated it as severe hypercholesterolemia and started a high-intensity statin without a risk calculation; every adult at that level is still eligible for a statin under the 2026 ACC/AHA guideline.
- Inherited hypercholesterolemia
- Diet high in saturated fat
- Hypothyroidism or kidney disease
- Drugs such as progestins or anabolic steroids
Sources: [8] [9] [2] [3] [18] [13]
A low result
Below 100 mg/dL is optimal. On treatment, lower LDL goes with lower risk.
- Statin or other lipid-lowering therapy
- Healthy diet and activity
How the test works
| Sample | Serum (preferred) or plasma, 1 mL at Labcorp. Labcorp rejects citrate tubes for direct LDL. |
|---|---|
| Fasting | Fasting is not required for a lipid panel or a direct LDL at Labcorp or Quest. The European Atherosclerosis Society and EFLM recommend routine non-fasting lipid profiles: after normal meals, the largest average changes are +26 mg/dL for triglycerides and -8 mg/dL for total and LDL cholesterol, while HDL does not change. They suggest a fasting sample when non-fasting triglycerides are above 440 mg/dL. |
| Timing | ATP III recommends a lipid profile every 5 years from age 20. On treatment, the 2026 ACC/AHA guideline reassesses after starting or changing therapy; the 2018 guideline it replaced rechecked at 4 to 12 weeks. |
| Lab differences | Usually calculated (Labcorp uses the NIH equation). Friedewald is less accurate at triglycerides of 400 mg/dL or more; a direct LDL assay avoids the calculation. |
| Retesting | The 2026 ACC/AHA guideline judges response by both the percentage fall from your own pre-treatment LDL and the level reached, so keep your baseline value from the same lab. |
| Labcorp order code | 303756: Lipid Panel (LDL calculated) |
| Labcorp order code | 120295: Low-density Lipoprotein Cholesterol (Direct) |
| Quest Diagnostics order code | 7600: Lipid Panel, Standard (LDL calculated) |
| Quest Diagnostics order code | 8293: Direct LDL |
| LOINC codes |
|
History
LDL went from a particle that needed an ultracentrifuge to measure to the main target of heart-disease prevention.
- 1972Friedewald and colleagues publish a way to estimate LDL cholesterol without the preparative ultracentrifuge. [10]
- 1986Brown and Goldstein describe the LDL-receptor pathway for cholesterol homeostasis. [6]
- 2003PCSK9 mutations are identified as a cause of autosomal dominant hypercholesterolemia. [7]
- 2010The Cholesterol Treatment Trialists show more intensive LDL lowering further reduces major vascular events. [1]
- 2020The NIH equation is published to calculate LDL more accurately at low LDL and high triglycerides. [4]
FAQ
What is a good LDL level?
Below 100 mg/dL is optimal for adults (ATP III). Labcorp prints 0-99 mg/dL and Quest below 100 for adults. If you have heart disease, your clinician may aim lower.
Is LDL measured or calculated?
Usually calculated from total cholesterol, HDL and triglycerides. Labcorp uses the NIH equation. A direct LDL test measures it and is useful when triglycerides are very high.
Do I need to fast for LDL?
No. A normal meal lowers LDL by about 8 mg/dL at most; Labcorp and Quest accept non-fasting samples.
What does an LDL of 190 or more mean?
Very high in ATP III. The 2018 AHA/ACC guideline called it severe hypercholesterolemia and started a high-intensity statin without calculating risk; the 2026 ACC/AHA guideline still makes every adult at that level eligible for a statin. Labcorp suggests considering familial hypercholesterolemia.
How much do statins lower LDL?
High-intensity statins typically lower LDL by 50% or more, moderate-intensity by 30% to 49% (2018 AHA/ACC). The 2026 ACC/AHA guideline uses the same bands: a 30-49% fall at borderline or intermediate risk and 50% or more at high risk.
Does lowering LDL actually prevent heart attacks?
Yes. In the Cholesterol Treatment Trialists' meta-analysis, more intensive statin therapy gave a further 15% reduction in major vascular events, including fewer heart attacks and strokes.
Sources: [1]
Why is my calculated LDL different from a direct LDL?
Calculations assume a fixed relation between triglycerides and VLDL. The Friedewald formula is less accurate when triglycerides are 400 mg/dL or more or LDL is low, which the NIH equation was built to improve.
Do GLP-1 drugs lower LDL?
Only a little. In obesity trials LDL fell 7.1% on Tirzepatide 15 mg (vs 1.7% on placebo), 2.5% on Semaglutide 2.4 mg and 3.1% on Liraglutide 3 mg.
Can peptides raise LDL?
GnRH drugs can: LDL rose 21.3 mg/dL over 6 months on Goserelin in women treated for endometriosis, and the Leuprolide label records hyperlipidemia including LDL.
Which conditions raise LDL?
ATP III lists diabetes, hypothyroidism, obstructive liver disease and chronic kidney failure, and drugs such as progestins, anabolic steroids and corticosteroids.
Sources: [8]
References
- Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81. PMID 21067804
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. PMID 30586774
- Labcorp. Sample report, test 303756 (Lipid Panel): reference intervals as printed for a 31-year-old woman (reported 06/10/2024). files.labcorp.com/testmenu-d8/sample_reports/303756.pdf
- Sampson M, Ling C, Sun Q, et al. A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia. JAMA Cardiol. 2020;5(5):540-548. PMID 32101259
- Labcorp. Test 120295: Low-density Lipoprotein Cholesterol (Direct). Methodology, patient preparation and LOINC map. labcorp.com/tests/120295/low-density-lipoprotein-cholesterol-direct
- Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232(4746):34-47. PMID 3513311
- Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154-6. PMID 12730697
- National Cholesterol Education Program. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive Summary. NIH Publication No. 01-3670. National Heart, Lung, and Blood Institute; 2001. Table 2 (LDL, total and HDL cholesterol classification), triglyceride classification and Table 8 (metabolic syndrome). nhlbi.nih.gov/files/docs/guidelines/atp3xsum.pdf
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97. PMID 11368702
- Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502. PMID 4337382
- Quest Diagnostics. Test 8293: Direct LDL. Test directory: methodology, patient preparation, reference range and clinical significance. testdirectory.questdiagnostics.com/test/test-detail/8293/direct-ldl?cc=PHP
- Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016;37(25):1944-58. PMID 27122601
- Writing Committee Members, Blumenthal RS, Morris PB, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154-e1276. PMID 41824552
- Sabouret P, Mafrica D, Giamundo DM, et al. The 2026 ACC/AHA Dyslipidemia Guideline: A Critical and Transatlantic Perspective on Personalized Lipid Management. Life (Basel). 2026;16(9). PMID 42795336
- Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572-80. PMID 22607825
- Labcorp. Sample report, test 120295 (LDL Cholesterol, Direct): reference interval as printed for a 32-year-old man (reported 06/10/2024). files.labcorp.com/testmenu-d8/sample_reports/120295.pdf
- Quest Diagnostics. Test 7600: Lipid Panel, Standard. Test directory: components, patient preparation, methodology and age- and sex-specific reference ranges. testdirectory.questdiagnostics.com/test/test-detail/7600/lipid-panel-standard?cc=PHP
- Essa M, Malik D, Narula S, et al. Primary prevention statin eligibility for U.S. adults under the 2026 ACC/AHA dyslipidemia guideline. Am J Prev Cardiol. 2026;30:101709. PMID 42827841
- Zoladex (goserelin implant) 3.6 mg. FDA prescribing information: lipid changes in women treated for endometriosis. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=294b168b-6e5f-4db9-bf70-d599271458b3
- Lupron Depot (leuprolide acetate) 7.5 mg, 22.5 mg, 30 mg, 45 mg. FDA prescribing information: Warnings (metabolic syndrome) and laboratory abnormalities. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cbc8f94e-7330-4465-05ad-16d64493a5dd
- Zepbound (tirzepatide) injection. FDA prescribing information, Table 3 (cardiometabolic parameters, Studies 1 and 2). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- Bobu AM, Turliuc S, Cucu AI, et al. Dulaglutide 1.5 mg Significantly Improves Glycemic Control and Lowers LDL-Cholesterol and Body Weight in Romanian Patients with Type 2 Diabetes. J Clin Med. 2025;14(10). PMID 40429530
- Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-11. PMID 18981485
- Svensson J, Jansson JO, Ottosson M, et al. Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a). J Clin Endocrinol Metab. 1999;84(6):2028-33. PMID 10372705
- Saxenda (liraglutide) injection 3 mg. FDA prescribing information, Table 6 (cardiometabolic parameters, Study 1). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
- Wegovy (semaglutide) injection 2.4 mg. FDA prescribing information, Table 10 (cardiometabolic parameters, Study 2). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- Labcorp. Test 303756: Lipid Panel. Components, specimen, patient preparation and LOINC map. labcorp.com/tests/303756/lipid-panel
Educational information, not medical advice. Lab ranges and test codes were checked on October 31, 2026. Always use the range printed on your own report, and talk to a clinician about your results.